MARTINSRIED (dpa-AFX) - MorphoSys AG (MPSYY.PK) said the US Patent and Trademark Office has granted a patent covering the company's cancer compound MOR202. The new patent covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled expiry date in 2028, not including any potential regulatory extensions. According to the company, MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia. The HuCAL-derived, fully human antibody is currently being tested in a phase 1/2a trial in patients with relapsed/refractory myeloma.
Copyright RTT News/dpa-AFX
